In addition, a preclinical study using ErbB-targeted T cells in combination with carboplatin has shown that treatment with the low-dose chemotherapeutic agent carboplatin increases the susceptibility of tumor cells to specific ErbB CAR-T cell-mediated cytotoxicity and enhances antitumor efficacy [160,161]. Here, EGFR is linked to neoplasm.